Abbott Laboratories (NYSE: ABT) on Tuesday, soared 1.44% from the previous trading day, before settling in for the closing price of $131.38. Within the past 52 weeks, ABT’s price has moved between $110.86 and $141.23.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 29.98%. The company achieved an average annual earnings per share of 10.22%. With a float of $1.73 billion, this company’s outstanding shares have now reached $1.74 billion.
Abbott Laboratories (ABT) Breakdown of a Key Holders of the stock
Observing investor behavior towards Medical Devices industry stocks is more important than anything else. The insider ownership of Abbott Laboratories is 0.67%, while institutional ownership is 80.06%. The most recent insider transaction that took place on Aug 08 ’25, was worth 746,758. In this transaction EVP AND CFO of this company sold 5,550 shares at a rate of $134.55, taking the stock ownership to the 51,003 shares. Before that another transaction happened on Aug 08 ’25, when Company’s Officer proposed sale 5,550 for $134.55, making the entire transaction worth $746,758.
Abbott Laboratories (ABT) Recent Fiscal highlights
As on 9/30/2024, Multinational firm has announced its last quarter scores, in which it reported 1.21 earnings per share (EPS) for the period topping the consensus outlook (set at 1.2) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.49 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 10.22% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 10.31% during the next five years compared to 29.98% growth over the previous five years of trading.
Abbott Laboratories (NYSE: ABT) Trading Performance Indicators
Abbott Laboratories (ABT) is currently performing well based on its current performance indicators. A quick ratio of 1.30 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.38. Likewise, its price to free cash flow for the trailing twelve months is 34.24.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 8.00, a number that is poised to hit 1.30 in the next quarter and is forecasted to reach 5.67 in one year’s time.
